Takeda and Affilogic partner to develop CNS therapies
Takeda Pharmaceutical Company and Affilogic have entered into a research collaboration to explore using Affilogic’s Nanofitins platform in therapies targeting the central nervous system (CNS).
Specifically, Affilogic and Takeda, through its research center in San Diego, California, will leverage their respective competencies to validate and optimize Nanofitins® that enable Takeda to deliver biotherapeutic candidates into the brain to address neurological disorders.
Click on this link for more information.
